AR035174A1 - Compuesto derivado de beta-aminoacido, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para tratar o prevenir trastornos inflamatorios y enfermedades mediadas por mmp, tnf y agrecansa y combinaciones de los mismos - Google Patents

Compuesto derivado de beta-aminoacido, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para tratar o prevenir trastornos inflamatorios y enfermedades mediadas por mmp, tnf y agrecansa y combinaciones de los mismos

Info

Publication number
AR035174A1
AR035174A1 ARP010101253A ARP010101253A AR035174A1 AR 035174 A1 AR035174 A1 AR 035174A1 AR P010101253 A ARP010101253 A AR P010101253A AR P010101253 A ARP010101253 A AR P010101253A AR 035174 A1 AR035174 A1 AR 035174A1
Authority
AR
Argentina
Prior art keywords
crara1
substituted
alkyl
nrara1
case
Prior art date
Application number
ARP010101253A
Other languages
English (en)
Inventor
Jingwu Duan
Carl Decicco
Thomas Maduskuie Jr
Matthew Voss
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of AR035174A1 publication Critical patent/AR035174A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)

Abstract

Compuesto derivado de b-aminoácido de la fórmula (1), o un estereoisómero o una forma de sal aceptable para uso farmacéutico del mismo, donde: A se selecciona entre -COR5, -CO2H, -CO2R6, -C(O)NHOH, -C(O)NHOR5, -C(O)NHOR6, -NHRa, -N(OH)COR5, -C(OH)CHO, -SH, -CH2SH, -S(O)(=NH)Ra, -S(=NH)2Ra, -SC(O)Ra, -PO(OH)2, y -PO(OH)NHRa; X está ausente o se selecciona entre alquileno C1-3, alquenileno C2-3, y alquinileno C2-3; Z está ausente o se selecciona entre un carbociclo C3-13 sustituido con 0-5 Rb y un heterociclo de 5 a 14 miembros que comprende átomos de carbono y 1-4 heteroátomos seleccionados del grupo forma por N, O y S(O)p y está sustituido con 0-5 Rb, Ua está ausente o se selecciona entre: O, NRa1, C(O), C(O)O, OC(O), C(O)NRa1, NRa1C(O), OC(O)O, OC(O)NRa1, NRa1C(O)O, NRa1C(O)NRa1, S(O)p, S(O)pNRa1, NRa1S(O)p, y NRa1SO2NRa1; Xa está ausente o se selecciona entre alquileno C1-10, alquenileno C2-10, y alquinileno C2-10; Ya está ausente o se selecciona entre O, NRa1, S(O)p, y C(O); Za se selecciona entre H, un carbociclo C3-13 sustituido con 0-5 Rc y un heterociclo de 5 a 14 miembros que comprende átomos de carbono y 1-4 heteroátomos seleccionados del grupo formado por N, O, y S(O)p y está sustituido con 0-5 Rc; con la condición de que Z, Ua, Ya y Za no se combinen para formar un grupo N-N, N-O, O-N, O-O, S(O)p-O, O-S(O)p o S(O)p-S(O)p; R1 se selecciona entre H, alquilo C1-4, fenilo y bencilo; R2 se selecciona entre Q, alquilen-Q C1-6, alquenilen-Q C2-6, alquinilen-Q C2-6, (CRaRa1)r1O(CRaRa1)r-Q, (CRaRa1)r1NRa(CRaRa1)r-Q, (CRaRa1)r1C(O)(CRaRa1)r-Q, (CRaRa1)r1C(O)O(CRaRa1)r-Q, (CRaRa1)r1OC(O)(CRaRa1)r-Q, (CRaRa1)r1C(O)NRaRa1, (CRaRa1)r1C(O)NRa(CRaRa1)r-Q, (CRaRa1)r1NRaC(O) (CRaRa1)r-Q, (CRaRa1)r1OC(O)O(CRaRa1)r-Q, (CRaRa1)r1OC(O)NRa(CRaRa1)r-Q, (CRaRa1)r1NRaC(O)O(CRaRa1)r-Q, (CRaRa1)r1NRaC(O)NRa(CRaRa1)r-Q, (CRaRa1)r1S(O)p(CRaRa1)r-Q, (CRaRa1)r1SO2NRa(CRaRa1)r-Q, (CRaRa1)r1NRaSO2(CRaRa1)r-Q, y (CRaRa1)r1NRaSO2NRa(CRaRa1)r-Q; Q se selecciona entre H, un carbociclo C3-13 sustituido con 0-5 Rd y un heterociclo de 5 a 14 miembros que comprende átomos de carbono y 1-4 heteroátomos seleccionados del grupo formado por N, O y S(O)p y está sustituido con 0-5 Rd; R3 se selecciona entre Q1, alquilen-Q1 C1-6, alquenilen-Q1 C2-6, alquinilen-Q1 C2-6, (CRaRa1)r1O(CH2)r-Q1, (CRaRa1)r1NRa(CRaRa1)r-Q1, (CRaRa1)r1NRaC(O) (CRaRa1)r-Q1, (CRaRa1)r1C(O)NRa(CRaRa1)r-Q1, (CRaRa1)r1C(O) (CRaRa1)r-Q1, (CRaRa1)r1C(O)O(CRaRa1)r-Q1, (CRaRa1)2r1S(O)p(CRaRa1)r-Q1, y (CRaRa1)r1SO2NRa(CRaRa1)r-Q1; Q1 se selecciona entre H, un carbociclo C3-13 sustituido con 0-5 Rd y un heterociclo de 5 a 14 miembros que comprende átomos de carbono y 1-4 heteroátomos seleccionados del grupo formado por N, O y S(O)p y está sustituido con 0-5 Rd; R4 se selecciona entre H, alquilo C1-6 sustituido con 0-1 Rb; alquenilo C2-6 sustituido con 0-1 Rb, y alquinilo C2-6 sustituido con 0-1 Rb; R4a se selecciona entre H, alquilo C1-6 sustituido con 0-1 Rb, alquenilo C2-6 sustituido con 0-1 Rb y alquinilo C2-6 sustituido con 0-1 Rb; como alternativa, R1 y R2 junto con los átomos de carbono y nitrógeno a los cuales están unidos se combinan para formar un anillo heterocíclico de 3 a 10 miembros que comprende átomos de carbono y, además del átomo de nitrógeno al cual R1 está unido, 0 a 2 heteroátomos del anillo seleccionados entre O, N, NRc y S(O)p y sustituido con 0-3 Rc; como alternativa, R1 y R3 junto con los átomos de carbono y nitrógeno a los cuales están unidos se combinan para formar un anillo heterocíclico de 4 a 6 miembros que comprende átomos de carbono y, además del átomo de nitrógeno al cual R1 está unido, 0 a 1 heteroátomos del anillo seleccionados entre O, N, NRc, y S(O)p y sustituidos con 0-1 Rc; como alternativa, R3 y R4a junto con el átomo de carbono al cual están unidos se combinan para formar un anillo carbocíclico o heterocíclico de 3 a 10 miembros que comprende átomos de carbono y 0 a 2 heteroátomos del anillo seleccionados entre O, N, NRc, y S(O)p y sustituidos con 0-3 Rc; con la condición de que 0 a 2 entre R1 y R2, R1 y R3 y R3 y R4a se combinen para forman un anillo; Ra, en cada caso, se selecciona independientemente entre H y alquilo C1-6; Ra1, en cada caso, se selecciona independientemente entre H, alquilo C1-6 sustituido con 0-1 Rc1, alquenilo C2-6 sustituido con 0-1 Rc1, alquinilo C2-6 sustituido con 0-1 Rc1, y anillo carbocíclico o heterocíclico -(CH2)r- de 3 a 8 miembros que comprende átomos de carbono y 0 a 2 heteroátomos del anillo seleccionados entre N, NRc1, O y S(O)p y sustituidos con 0-3 Rc1; como alternativa, Ra y Ra1 cuando están unidos a un átomo de nitrógeno se toman junto con el átomo de nitrógeno al cual están unidos para formar un heterociclo de 5 a 6 miembros que comprende átomos de carbono y entre 0 y 1 heteroátomos adicionales seleccionados entre N, NRa2, O, y S(O)p; Ra2, en cada caso, se selecciona independientemente entre alquilo C1-4, fenilo, y bencilo; Ra3, en cada caso, se selecciona independientemente entre H, alquilo C1-6 sustituido con 0-1 Rc1, alquenilo C2-6 sustituido con 0-1 Rc1, alquinilo C2-6 sustituido con 0-1 Rc1, y anillo carbocíclico o heterocíclico -(CH2)r- de 3 a 8 miembros que comprende átomos de carbono y 0 a 2 heteroátomos del anillo seleccionados entre N, NRc1, O, y S(O)p y sustituido con 0-3 Rc1; Rb, en cada caso, se selecciona independientemente entre alquilo C1-6 sustituido con 0-1 Rc1, ORa, Cl, F, Br, I, =O, -CN, NO2, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, C(S)NRaRa1, NRaC(O)NRaRa1, OC(O)NRaRa1, NRaC(O)ORa, S(O)2NRaRa1, NRaS(O)2Ra3, NRaS(O)2NRaRa1, OS(O)2NRaRa1, NRaS(O)2Ra3, S(O)pRa3, CF3, y CF2CF3; Rc, en cada caso, se selecciona independientemente entre H, alquilo C1-6 sustituido con 0-2 Rc1, alquenilo C2-6 sustituido con 0-2 Rc1, alquinilo C2-6 sustituido con 0-2 Rc1; ORa, Cl, F, Br, I, =O, -CN, NO2, (CRaRa1)r1NRaRa1, CF3, CF2CF3, (CRaRa1)r1C(=NCN)NRaRa1, (CRaRa1)r1C(=NRa)NRaRa1, (CRaRa1)r1C(=NORa)NRaRa1, (CRaRa1)r1C(O)NRaOH, (CRaRa1)r1C(O)Ra1, (CRaRa1)r1C(O)ORa1, (CRaRa1)r1C(S)ORa1, (CRaRa1)r1C(O)NRaRa1, (CRaRa1)r1NRaC(O)Ra1, (CRaRa1)r1C(S)NRaRa1, (CRaRa1)r1OC(O)NRaRa1, (CRaRa1)r1NRaC(O)ORa1, (CRaRa1)r1NRaC(O)NRaRa1, (CRaRa1)r1S(O)pRa3, (CRaRa1)r1SO2NRaRa1, (CRaRa1)r1NRaSO2Ra3, y (CRaRa1)r1NRaSO2NRaRa1, un carbociclo C3-10 sustituido con 0-2 Rc1, (CRaRa1)r1-C3-10 carbociclo sustituido con 0-2-Rc1, un heterociclo de 5 a 14 miembros que comprende átomos de carbono y 1-4 heteroátomos seleccionados del grupo formado por N, O y S(O)p y sustituido con 0-2 Rc1, y (CRaRa1)r1- heterociclo de 5-14 miembros que comprende átomos de carbono y 1-4 heteroátomos seleccionados del grupo formado por N, O y S(O)p y sustituido con 0-2 Rc1; Rc1, en cada caso, se selecciona independientemente entre H, alquilo C1-4, ORa, Cl, F, Br, I, =O, CF3, -CN, NO2, C(O)ORa, y C(O)NRaRa1; Rd, en cada caso, se selecciona independientemente entre alquilo C1-6, ORa, Cl, F, Br, I, =O, -CN, NO2, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, C(S)NRaRa1, RaNC(O)NRaRa1, OC(O)NRaRa1, RaNC(O)O, S(O)2NRaRa1, NRaS(O)2Ra3, NRaS(O)2NRaRa1, OS(O)2NRaRa1, NRaS(O)2Ra3, S(O)pRa3, CF3, CF2CF3, un carbociclo C3-10 y un heterociclo de 5 a 14 miembros que comprende átomos de carbono y 1-4 heteroátomos seleccionados del grupo formado por N, O, y S(O)p; R5, en cada caso, se selecciona entre alquilo C1-10 sustituido con 0-2 Rb, y alquilo C1-8 sustituido con 0-2 Re; R8, en cada caso, se selecciona entre fenilo sustituido con 0-2 Rb y bifenilo sustituido con 0-2 Rb; R6, en cada caso, se selecciona entre fenilo, naftilo, C1-10 alquil-fenil-C1-6 alquil-, cicloalquilo C3-11, C1-6 alquilcarboniloxi--C1-3 alquil-, C1-6 alcoxicarboniloxi-C1-3 alquil-, alcoxicarbonilo C2-10, C3-6 cicloalquilcarboniloxi-C1-3 alquil-, C3-6 cicloalcoxicarboniloxi-C1-3 alquil-, C3-6 cicloalcoxicarbonilo, fenoxicarbonilo, feniloxicarboniloxi-C1-3 alquil-, fenilcarboniloxi-C1-3 alquil-, C1-6 alcoxi-C1-6 alquilcarboniloxi-C1-3 alquil-, [5-(C1-5 alquil)-1,3-dioxa-ciclopenten-2-ona-il]metilo, [5-(Ra)-1,3-dioxa-ciclopenten-2-ona-il]metilo, (5-aril-1,3-dioxa-ciclopenten-2-ona-il)metilo, -C1-10 alquil-NR7R7a, -CH(R8)OC(=O)R9, y CH(R8)OC(=O)OR9; R7 se selecciona entre H y alquilo C1-10, alquenilo C2-6, C3-6 cicloalquil-C1-3 alquil-, y fenil-C1-6 alquil-; R7a se selecciona entre H y alquilo C1-10, alquenilo C2-6, C3-6 cicloalquil-C1-3 alquil-, y fenil-C1-6 alquil-; R8 se selecciona entre H y alquilo C1-4 lineal; R9 se selecciona entre H, alquilo C1-8 sustituido con 1-2 Rf, cicloalquilo C3-8 sustituido con 1-2 Rf, y fenilo sustituido con 0-2 Rb; Rf, en cada caso, se selecciona entre alquilo C1-4, cicloalquilo C3-8, alcoxi C1-5, y fenilo sustituido con 0-2 Rb; p, en cada caso, se selecciona entre 0, 1 y 2; r, en cada caso, se selecciona entre 0, 1, 2, 3 y 4; y, r1, en cada caso, se selecciona entre 0, 1, 2, 3, y 4; con la condición de que cuando ninguno de los pares R1 y R2, R1 y R3 y R3 y R4a se combina para formar un anillo: (a) X-Z-Ua-Xa-Ya-Za forma grupos distintos de los representados por Z-O-Za, Z-S-Za y Z-C(O)-Za, y (b) Ua-Xa-Ya-Za forma grupos distintos de un grupo alcoxi. La composición farmacéutica que comprende estos compuestos así como su uso en la fabricación de medicamentos útiles para tratar o prevenir trastornos inflamatorios o enfermedades mediadas por MMP, TNF y/o agrecanasa, también se describen.
ARP010101253A 2000-03-17 2001-03-16 Compuesto derivado de beta-aminoacido, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para tratar o prevenir trastornos inflamatorios y enfermedades mediadas por mmp, tnf y agrecansa y combinaciones de los mismos AR035174A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19018300P 2000-03-17 2000-03-17
US23546700P 2000-09-26 2000-09-26
US25206200P 2000-11-20 2000-11-20

Publications (1)

Publication Number Publication Date
AR035174A1 true AR035174A1 (es) 2004-05-05

Family

ID=27392702

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101253A AR035174A1 (es) 2000-03-17 2001-03-16 Compuesto derivado de beta-aminoacido, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para tratar o prevenir trastornos inflamatorios y enfermedades mediadas por mmp, tnf y agrecansa y combinaciones de los mismos

Country Status (15)

Country Link
US (1) US6495565B2 (es)
EP (1) EP1263756B1 (es)
JP (1) JP2003528097A (es)
CN (1) CN1420881A (es)
AR (1) AR035174A1 (es)
AT (1) ATE260272T1 (es)
AU (1) AU2001250850A1 (es)
BR (1) BR0109469A (es)
CA (1) CA2400168A1 (es)
DE (1) DE60102137T2 (es)
ES (1) ES2215893T3 (es)
HK (1) HK1049334B (es)
IL (1) IL151018A0 (es)
NZ (1) NZ521245A (es)
WO (1) WO2001070734A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
PE20030320A1 (es) 2001-07-17 2003-04-03 Gruenenthal Chemie Derivados sustituidos de 4-aminociclohexanol
DE10162701A1 (de) * 2001-12-19 2003-07-03 Merck Patent Gmbh Pyrrolsynthese
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
EP1613269B1 (en) 2003-04-04 2015-02-25 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
US7842835B2 (en) 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
WO2005012221A1 (ja) * 2003-08-04 2005-02-10 Ono Pharmaceutical Co., Ltd. ジフェニルエーテル化合物、その製造方法および用途
PL1656348T4 (pl) 2003-08-20 2007-07-31 Pharmacyclics Inc Pochodne acetylenu jako inhibitory deacetylazy histonowej
WO2005035471A1 (ja) 2003-10-14 2005-04-21 Ajinomoto Co., Inc. エーテル誘導体
CA2553433A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
CN1933839A (zh) 2004-01-23 2007-03-21 安进公司 化合物和使用方法
SE0400850D0 (sv) * 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
PE20060426A1 (es) * 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7638513B2 (en) * 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
US7488745B2 (en) * 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7482370B2 (en) 2004-07-16 2009-01-27 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) * 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
TW200626532A (en) * 2004-09-21 2006-08-01 Syngenta Participations Ag Novel insecticides
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1893583B1 (en) 2005-05-31 2012-04-04 Pfizer Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
PE20071240A1 (es) * 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
JP5205971B2 (ja) * 2006-01-27 2013-06-05 宇部興産株式会社 テトラヒドロピラン化合物の製造方法
EP1996589A1 (en) * 2006-03-17 2008-12-03 RaQualia Pharma Inc Chromane derivatives
JP2009532504A (ja) 2006-04-06 2009-09-10 グラクソ グループ リミテッド 抗菌薬
EP2041181B1 (en) * 2006-06-08 2011-05-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Specific protease inhibitors and their use in cancer therapy
WO2008019284A1 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of lta4h for treating inflammation
US8410150B2 (en) * 2007-03-09 2013-04-02 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
WO2008118758A1 (en) 2007-03-23 2008-10-02 Icagen, Inc. Inhibitors of ion channels
JP5539864B2 (ja) * 2007-06-12 2014-07-02 アカオゲン，インコーポレーテッド 抗菌剤
US8680282B2 (en) * 2007-08-01 2014-03-25 University Health Network Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
EP2020413A1 (de) 2007-08-02 2009-02-04 Bayer CropScience AG Oxaspirocyclische-spiro-substituierte Tetram- und Tetronsäure-Derivate
TW201024303A (en) 2008-09-24 2010-07-01 Schering Corp Compounds for the treatment of inflammatory disorders
AR073307A1 (es) 2008-09-24 2010-10-28 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
EP2355825A2 (en) 2008-11-10 2011-08-17 Schering Corporation Compounds for the treatment of inflammatory disorders
EP2356111A1 (en) 2008-11-10 2011-08-17 Schering Corporation Compounds for the treatment of inflammatory disorders
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
FR2950057B1 (fr) 2009-09-17 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2950056B1 (fr) 2009-09-17 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
EP2483254B1 (en) 2009-09-29 2014-08-13 Glaxo Group Limited Novel compounds
SG188329A1 (en) * 2010-09-03 2013-04-30 Lg Life Sciences Ltd Production method of intermediate compound for synthesizing medicament
CN104066729A (zh) 2011-08-15 2014-09-24 英特穆恩公司 溶血磷脂酸受体拮抗剂
CN102936216B (zh) * 2012-12-05 2015-03-04 南京药石药物研发有限公司 7,9-二氧代-2,6-氮杂-螺[3.5]壬-2-甲酸叔丁酯及其中间体的制备方法
WO2014139080A1 (en) * 2013-03-12 2014-09-18 Boehringer Ingelheim International Trading (Shanghai) Co., Ltd. Novel process for the manufacture of 3-oxo-tetrahydrofuran
MY192489A (en) 2013-10-14 2022-08-23 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
BR112016008378B1 (pt) 2013-10-14 2022-11-08 Eisai R&D Management Co., Ltd Compostos de quinolina seletivamente substituídos ou sal dos mesmos, e composição farmacêutica contendo os ditos compostos
CN103965097A (zh) * 2014-05-22 2014-08-06 南开大学 一种2-哌啶酮的制备方法
CN104311473B (zh) * 2014-05-27 2016-09-28 斯芬克司药物研发（天津）股份有限公司 一种哌啶类化合物及其制备方法
WO2016105448A1 (en) * 2014-12-22 2016-06-30 Darryl Rideout Imidazoline receptor type 1 ligands for use as therapeutics
EP3199534B1 (en) * 2016-02-01 2018-09-05 Galderma Research & Development Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
CN110498750B (zh) * 2019-09-02 2021-10-15 南通大学 一种(r)-4-羟基-1-甲氧基丁-2-基氨基甲酸叔丁酯的合成方法
WO2023191425A1 (ko) * 2022-03-28 2023-10-05 주식회사 비엔에이치리서치 약물의 전기생리학적 스크리닝 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02256667A (ja) * 1988-12-27 1990-10-17 Masatoshi Yamato 縮合キノリン系化合物およびその製造方法
US5212182A (en) * 1990-10-03 1993-05-18 American Home Products Corpooration Substituted quinolinyl- and naphthalenylbenzamides or benzylamines and related compounds useful as analgesics
HUP9902092A3 (en) * 1995-12-08 2000-12-28 Agouron Pharmaceuticals Inc La Metalloproteinase inhibitor benzenesulfonamide derivatives, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
EP0818442A3 (en) * 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
AUPP982399A0 (en) 1999-04-19 1999-05-13 Fujisawa Pharmaceutical Co., Ltd. Mmp inhibitor

Also Published As

Publication number Publication date
DE60102137T2 (de) 2004-10-21
EP1263756A2 (en) 2002-12-11
IL151018A0 (en) 2003-02-12
WO2001070734A3 (en) 2002-03-14
ATE260272T1 (de) 2004-03-15
CA2400168A1 (en) 2001-09-27
ES2215893T3 (es) 2004-10-16
BR0109469A (pt) 2003-04-29
HK1049334A1 (en) 2003-05-09
WO2001070734A2 (en) 2001-09-27
US6495565B2 (en) 2002-12-17
HK1049334B (zh) 2004-07-16
DE60102137D1 (de) 2004-04-01
JP2003528097A (ja) 2003-09-24
AU2001250850A1 (en) 2001-10-03
EP1263756B1 (en) 2004-02-25
CN1420881A (zh) 2003-05-28
US20020013341A1 (en) 2002-01-31
NZ521245A (en) 2004-04-30

Similar Documents

Publication Publication Date Title
AR035174A1 (es) Compuesto derivado de beta-aminoacido, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para tratar o prevenir trastornos inflamatorios y enfermedades mediadas por mmp, tnf y agrecansa y combinaciones de los mismos
AR035710A1 (es) Compuesto derivado de beta-aminoacidos ciclicos, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento para el tratamiento de una enfermedad mediada por mmps, tnf, agrecanasa y combinaciones de los mismos
AR119731A1 (es) Inhibidores del inflamasoma nlrp3
AR036875A1 (es) Acidos hidroxamicos ciclicos como inhibidores de las metaloproteinasas de matriz y/o de la enzima de conversion del factor de necrosis de tumor alfa
AR048939A1 (es) Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios.
AR117490A1 (es) Inhibidores de kif18a
AU779994B2 (en) Inhibitors of aspartyl protease
ES2531315T3 (es) Compuestos de fosfinato antivíricos
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
AR047962A1 (es) Combinacion de agonistas de adrenoceptor beta-2 y corticosteroides para el tratamiento de enfermedades respiratorias
AR088218A1 (es) Compuestos heterociclicos utiles como inhibidores de pi3k
EA200600527A1 (ru) Активирующее ppar соединение и содержащая его фармацевтическая композиция
AR082152A1 (es) Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
AR037676A1 (es) Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulacion; composicion farmaceutica que los comprende y procedimiento para preparar compuestos de formula (i)
AR057244A1 (es) Compuestos agonistas,antagonistas o agonistas inversos de receptores cb2,composiciones farmaceuticas que los contienen, metodos de preparacion y usos para tratar enfermedades inflamatorias y/o autoinmunes.
RU2007118727A (ru) Ингибиторы mif
AR079554A1 (es) Indazoles aminotiazolona sustituidos moduladores de receptores alfa relacionados con estrogenos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar artritis, diabetes, dislipemias y otras enfermedades.
AR030243A1 (es) Carboxamidas heterociclicas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento antiviral y metodo in vitro para inhibir el adn polimerasa viral
AR087470A1 (es) Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen
PE20212070A1 (es) Moduladores de trex1
AR058055A1 (es) Analogos de feniletilamina y su uso para el tratamiento del glaucoma
RU2008129641A (ru) Ингибиторы ccr9 активности
AR077819A1 (es) Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip)
AR048808A1 (es) Pirrolocarbazoles fusionados

Legal Events

Date Code Title Description
FB Suspension of granting procedure